Limited pharmacological treatments for uterine leiomyomata (fibroids) are available. Now, two phase III trials lasting 24 weeks showed marked reduction in leiomyoma-related heavy menstrual bleeding with relugolix, a new orally active gonadotropin-releasing hormone antagonist with add-back oestrogen (to limit bone loss) and progestin (to limit endometrial changes from unopposed oestrogen).
- Donna D. Baird
- Quaker E. Harmon
